Lodonal (naltrexone low dose oral) / Biostax Corp, Statera BioPharma - LARVOL DELTA

Same Drug, New Tricks: A Case Highlighting Low-Dose Naltrexoneâs Therapeutic Potential in Crohnâs Disease (ACG 2026) - "Vedolizumab was initiated in November 2021 with clinical improvement...Therapy was transitioned to Ustekinumab in March 2024, though loose stools persisted...LDN is reported to be beneficial in CD but data are still limited. Nevertheless, LDN can be an effective option for treatment-resistant patients."

Clinical • Crohn's disease • Gastroenterology • Immunology • Infectious Disease • Inflammatory Bowel Disease • IL23A • TLR4

The efficacy of low-dose naltrexone in improving self-reported physical health in patients with vasculitis: The LoDoNaVasc trial (ACR Convergence 2026) - "Patients with vasculitis were eligible if their vasculitis was in remission or very low disease activity, and doses of immunosuppressive therapies (including prednisone) or medications to treat pain, fatigue, or mood, were stable ≥12 weeks. The LoDoNaVasc trial demonstrated no benefit of LDN over placebo in patients reporting reduced global physical health. This trial addressed an issue important to both patients and clinicians, using a patient-reported measure as the primary outcome."

Clinical • ANCA Vasculitis • Inflammation • Vasculitis

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Arkansas | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Sustained Disease Control in Refractory Hailey-Hailey Disease with Low-Dose Naltrexone and Adjunctive CO₂ Laser Ablation (EADV 2026) - No abstract available

Genetic Disorders

Low-dose naltrexone in the treatment of Hailey–Hailey disease: a case report of refractory disease with significant clinical response (EADV 2026) - No abstract available

Case report • Clinical • Genetic Disorders

Low-Dose Naltrexone for Refractory Hailey-Hailey Disease: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Genetic Disorders

Low-Dose Naltrexone Promising for Long COVID: A 230-Patient Longitudinal Retrospective Study (IDWeek 2026) - No abstract available

Retrospective data • Infectious Disease • Novel Coronavirus Disease

Low-Dose Naltrexone in Crohn's Disease: A Prematurely Terminated Randomized Trial Showing Reduced Fatigue Without Clinical or Endoscopic Benefit. (PubMed, Dig Dis Sci) - "LDN was not effective for inducing remission in CD and showed no benefit over placebo. Despite not being an effective treatment for clinical and endoscopic outcomes, it may enhance better quality of life by reducing fatigue symptoms. Future studies are needed to clarify its potential benefit on fatigue in patients with inflammatory bowel disease."

Journal • Crohn's disease • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Integrated in silico and in vivo approaches reveal naltrexone as a synergistic modulator of TLR4 and μ-opioid receptors restoring redox homeostasis via Nrf2/Keap-1/HO-1 and HIF-1α/VEGF pathways in COPD. (PubMed, Mol Cell Biochem) - "Present study explores the therapeutic potential of ultra-low dose naltrexone (ULDN; 10 µg/kg body weight (BW), 1 µg/kg BW and 0.1 µg/kg BW) in mitigating cigarette smoke (CS) induced pulmonary inflammation and injury via modulation of key immunoinflammatory pathways. Our study evaluated that the lowest dose of NTX (0.1 µg/kg BW) exhibited the most pronounced therapeutic effects compared with 1 µg/kg BW and 10 µg/kg BW. This dose exhibiting strongest anti-inflammatory and antioxidant efficacy in COPD by inhibition of TLR4 and µOR signalling, highlights its potential as a dual-target therapeutic strategy against oxidative stress and airway inflammation."

IO biomarker • Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • CASP3 • CAT • HIF1A • KEAP1 • MPO • TLR4

Low Dose Naltrexone in Fibromyalgia - A randomised controlled cross-over trial (ANZCTR) - P2 | N=90 | Recruiting | Sponsor: The University of Queensland | Not yet recruiting ➔ Recruiting | Phase classification: P4 ➔ P2

Enrollment open • Phase classification • Fibromyalgia • Musculoskeletal Pain • Rheumatology

A Young Patient with Chronic Pain and Suspected Ehlers-Danlos Syndrome and Postural Orthostatic Tachycardia Syndrome (ASA 2026) - "Symptom improvement was partially achieved with a multimodal pain regimen including low-dose naltrexone. This case highlights the complexity of chronic pain management in patients with suspected connective tissue and autonomic disorders and emphasizes a multidisciplinary, individualized approach to care."

Clinical • Burkitt Lymphoma • Cardiovascular • Genetic Disorders • Hematological Malignancies • Leukemia • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Stellate Ganglion Block in Long Covid Syndrome (ASA 2026) - "Stellate ganglion block (SGB) has emerged as a promising sympatholytic intervention.A 28-year-old male with Long COVID presented with diffuse pain, tremors, vision changes, skin mottling, migraines, anxiety, and sleep disruption refractory to physical therapy, low-dose naltrexone, and corticosteroids. He underwent right-sided ultrasound-guided SGB with bupivacaine and dexamethasone. At three-week follow-up, he reported approximately 50% improvement in mood, cognition, pain, and dizziness.SGB represents a viable intervention for Long COVID-related autonomic dysfunction. Prospective trials are warranted."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Infectious Disease • Migraine • Mood Disorders • Movement Disorders • Novel Coronavirus Disease • Respiratory Diseases • Sleep Disorder

Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial. (PubMed, Pain Manag Nurs) - "Response rates for 30% improvement in six selected nonpain outcomes were similar after 12 weeks treatment with LDN or placebo in women with FM. Larger studies investigating 30% response rates are warranted."

Journal • CNS Disorders • Depression • Fatigue • Fibromyalgia • Musculoskeletal Pain • Pain • Psychiatry • Rheumatology • Sleep Disorder

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Arkansas | Trial completion date: Jan 2029 ➔ Jan 2030 | Trial primary completion date: Jan 2028 ➔ Jan 2029

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Persistent Sacroiliac Joint Pain After Joint Fusion Resolves With Radiofrequency Ablation of Lateral Sacral Nerve Branches: A Case Report. (PubMed, Pain Med Case Rep) - "Lateral branch block with subsequent RFA has utility in treating post-SIJ fusion pain, but has not been explored in the literature and may be a topic of future exploration in regard to treating this condition."

Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology

Low dose naltrexone for fibromyalgia: case series demonstrating pain relief and other health benefits. (PubMed, Front Pain Res (Lausanne)) - "LDN's proposed mechanism involving hormesis at opioid receptors and its implications for customized dosing in clinical care and research trials are discussed. While not all patients respond to LDN, this medication shows promise as an effective and safe intervention and deserves to be considered as a treatment recommendation for fibromyalgia."

Journal • CNS Disorders • Fibromyalgia • Insomnia • Musculoskeletal Pain • Pain • Rheumatology • Sleep Disorder

Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. (PubMed, BMJ Open) - "Limited evidence from small pre-post studies suggests LDN may improve fatigue, cognition, sleep, pain and functioning in long covid. However, certainty of evidence is low. Well-powered trials are needed to confirm efficacy, determine dosing and duration and identify subgroups most likely to benefit."

Journal • Retrospective data • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain

Low-dose Naltrexone for Bladder Pain Syndrome (clinicaltrials.gov) - P2 | N=29 | Terminated | Sponsor: Stanford University | Suspended ➔ Terminated; Study terminated due to early participant drop out

Trial termination • Interstitial Cystitis • Musculoskeletal Pain • Pain

Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study). (PubMed, Eur J Pain) - "This RCT provides the first long-term evidence on the efficacy and safety of LDN in FMS. LDN (4.5 mg), administered as an add-on treatment, has a favourable safety profile, but the findings indicate that it does not produce clinically meaningful improvements in FMS symptoms compared to placebo at short- or long-term follow-up. These findings contribute to the growing body of evidence questioning its clinical utility."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Fibromyalgia • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry • Rheumatology

Fibromyalgia - a complex construct with a multidisciplinary approach (CINP 2026) - "There are three drugs approved by FDA: pregabalin, duloxetine, and milnacipran. Duloxetine and milnacipran should be used in comorbid depression; Amitriptyline is recommended for sleep disturbances, while nortriptyline is better suited to treat fatigue. Antiepileptics (gabapentin, pregabalin) have been shown to modulate pain, promote physiological sleep, and act as an anxiolytic. Other pharmacologic options for treatment of pain include tramadol, low-dose naltrexone, and NMDA receptor antagonists. Armodafinil and methylphenidate improve fatigue and mood, and increase concentration; however, they require further clinical trials.Interestingly, the administration of placebo has proven more effective than no treatment in many clinical settings... Optimal management requires prompt diagnosis and providing the patient with information about the condition. There should be a comprehensive assessment of pain, function and the psychosocial context.It is recommended that..."

CNS Disorders • Cognitive Disorders • Depression • Fibromyalgia • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Rheumatology • Sleep Disorder

Therapeutic advances in fibromyalgia: one year in review 2026. (PubMed, Clin Exp Rheumatol) - "Among pharmacological treatments, low-dose naltrexone (LDN) continues to show potential benefits in modulating neuroinflammation and central sensitisation...Complementary and body-oriented interventions are also being explored for their potential impact on pain perception and emotional well-being.Overall, current evidence supports a biopsychosocial and multimodal approach, integrating pharmacological and non-pharmacological strategies tailored to individual patient profiles. Future research should focus on better phenotyping of patients and on identifying predictors of treatment response to optimise personalised management."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Fatigue • Fibromyalgia • Inflammation • Musculoskeletal Pain • Pain • Rheumatology • Sleep Disorder

Low-Dose Naltrexone in the Perioperative Setting: An Emerging Clinical Challenge. (PubMed, Ir J Med Sci) - No abstract available

Journal

MTP14 - Hormone Balancing: Addressing Social Media Myths (ENDO 2026) - "To highlight some of the most prominent conditions and potentially dangerous treatments, we will discuss adrenal fatigue, Wilsons syndrome, reverse T3 syndrome, low testosterone in women and low-dose naltrexone therapy. We will also discuss disorders that are mistakenly diagnosed as endocrine disorders due to assay interference. The talk will end with a discussion of a patient-centered and compassionate approach to managing patients who have been diagnosed with pseudo-endocrine disorders."

Endocrine Disorders • Metabolic Disorders • Nephrology

The Use of Naltrexone to Successfully Treat Severe Hailey-Hailey Disease. (PubMed, Cureus) - "In 2022, acitretin was commenced and uptitrated to 25 mg once daily...Other immunosuppressive agents, such as methotrexate, cyclosporine, and azathioprine, have been described in the literature with varying efficacy...Naltrexone is postulated to work due to its analgesic and anti-inflammatory effects. It is a well-tolerated treatment for severe HHD that has drastically improved both our patient's skin and his quality of life."

Journal • Addiction (Opioid and Alcohol) • Dermatology • Genetic Disorders • Oncology • Pain • Substance Abuse • IL6 • TLR4

CeASE: Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (clinicaltrials.gov) - P4 | N=78 | Recruiting | Sponsor: University Health Network, Toronto | Not yet recruiting ➔ Recruiting

Enrollment open • Novel Coronavirus Disease